LILLE, France – Academia's position as the major source of new innovation for pharma and biotech has, arguably, never been more secure. But the process of transferring innovation from an academic to an industry environment remains suboptimal, particularly in Europe, where the innovation ecosystem for biotechnology is less mature than that of the U.S.
DUBLIN – Proprotein convertase subtilisin–kexin type 9 (PCSK9) inhibitors are as good as but no better than statins in reducing the risk of cardiovascular events in patients with cardiovascular disease, according to a large-scale Mendelian randomization study published this week in the New England Journal of Medicine.
DUBLIN – Zealand Pharma A/S has attained the most significant milestone in its 18-year history, the FDA approval of Sanofi SA's type 2 diabetes combo product, Soliqua 100/33 (insulin glargine and lixisenatide injection, or Lixilan), which adds Zealand's glucagon-like peptide receptor agonist Adlyxin (lixisenatide) to the big pharma firm's basal insulin in a fixed-dose pen.
DUBLIN – Morphosys AG is, after a long haul, finally within touching distance of having one of its Hucal antibodies on the market, following a BLA filing in psoriasis by partner Janssen Research & Development LLC in support of guselkumab, which targets the p19 subunit of interleukin-23 (IL-23.).
DUBLIN – The still-tentative dalliance between immuno-oncology and gut microbiome research could blossom into a full-on romance, as Bristol-Myers Squibb Co. and Enterome Bioscience SA entered a broadly based pact focused on biomarker, target and drug discovery, which involves $15 million up front plus undisclosed milestones.
DUBLIN – The EMA launched a formal consultation process Tuesday on the development of a new guideline for first-in-human and early stage clinical trials of investigational drugs.
COLOGNE, Germany – As the curtain closed on the 22nd annual BIO-Europe Fall meeting Wednesday, the tumultuous election news from the U.S. was the main topic of conversation among delegates. The future prospects for European biotechnology were a secondary consideration for many.
COLOGNE, Germany – Alignment and differentiation emerged as the two key requirements for successful partnerships during a panel discussion on the transformational deals that shaped the biopharma industry during 2016, here at BIO-Europe on Tuesday.
COLOGNE, Germany – There are few countries to rival Germany for supplying gloomy gray weather in November. It's always a danger to rely too heavily on pathetic fallacy to describe the state of the biopharma industry, but to delegates arriving at the Koeln Messe Congress Centre for the 22nd annual BIO-Europe Fall meeting, the heavy clouds hanging over the cold waters of the Rhine seemed an apt metaphor for its current prospects.
DUBLIN – Turnstone Biologics Inc. raised $41.1 million in a series B round to accelerate clinical development of its next-generation oncolytic virus and cancer vaccine platform by deploying the technology in different combination settings, cancer indications and with different antigenic payloads.
